Spinocerebellar Ataxia
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Spinocerebellar Ataxia

View Main Condition: Movement Disorders

What is the definition of Spinocerebellar Ataxia?
Spinocerebellar ataxia is a genetic disorder that has many different types. Ataxia is a term that refers to difficulties with movement, balance, coordination, and speech. Spinocerebellar ataxia can appear at any age and is a progressive disorder.
What are the symptoms of Spinocerebellar Ataxia?
Symptoms of spinocerebellar ataxia depend on the type. Symptoms of spinocerebellar ataxia may appear suddenly or develop over time. Common symptoms of spinocerebellar ataxia include weakness, loss of sensation, and difficulty with eye movements. Additional symptoms of spinocerebellar ataxia may include back-and-forth eye movements, clumsiness, slurred speech, difficulty swallowing, loss of fine motor skills, muscle tremors, decreased coordination, difficulty walking, wide-set gait, impaired balance, frequent falls, and heart problems.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Spinocerebellar Ataxia?
There is currently no cure for spinocerebellar ataxia. Treatment for spinocerebellar ataxia depends on the type. Treatment for spinocerebellar ataxia is focused on managing the symptoms and improving mobility. Treatments for symptoms of spinocerebellar ataxia may include medications; physical therapy; occupational therapy; speech therapy; and assistive mobility devices, such as modified eating utensils, communication aids, canes, hiking sticks, walker, wheelchair, or motorized scooter.
Who are the top Spinocerebellar Ataxia Local Doctors?
Elite in Spinocerebellar Ataxia
Neurology
Elite in Spinocerebellar Ataxia
Neurology
Referral may be required
259 E Erie St Ste 1900, Lavin Family Pavilion, 
Chicago, IL 
Experience:
37+ years
Languages Spoken:
English
Offers Telehealth

Puneet Opal is a Neurologist practicing medicine in Chicago, Illinois. He has been practicing medicine for over 37 years. Dr. Opal is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Spinocerebellar Ataxia Type 1, Olivopontocerebellar Atrophy, Giant Axonal Neuropathy, and Spinocerebellar Ataxia. Dr. Opal is board certified in American Board Of Psychiatry And Neurology - Neurology (Certified).

Elite in Spinocerebellar Ataxia
Elite in Spinocerebellar Ataxia
Referral may be required

East Ann Arbor Health & Geriatrics Center

4260 Plymouth Rd, Level 1, 
Ann Arbor, MI 
Languages Spoken:
English
Offers Telehealth

Henry L. Paulson, M.D., Ph.D., is the Lucile Groff Professor of Neurology for Alzheimer's Disease and Related Disorders in the Department of Neurology at the University of Michigan. Dr. Paulson joined the U-M faculty in 2007, and he currently directs the Michigan Alzheimer’s Disease Center (MADC) and co-direct the U-M Protein Folding Diseases Initiative.Dr. Paulson received his medical degree and doctorate in Cell Biology from Yale University in 1990. He then completed a neurology residency and neurogenetics/movement disorders fellowships at the University of Pennsylvania. In 1997, he joined the Neurology faculty at the University of Iowa, where he remained until 2007.Dr. Paulson's research and clinical interests concern the causes and treatment of age-related neurodegenerative diseases, with an emphasis on polyglutamine diseases, Alzheimer's disease and frontotemporal dementia. In 1997, his lab described abnormal protein aggregates in the polyglutamine diseases, which now are recognized as a pathological hallmark in this important class of inherited diseases. Using test tube, cell-based and animal models, he has contributed to advances in the understanding of various neurodegenerative diseases. His lab also has helped pioneer the use of gene silencing methods as potential therapy for the many neurological disorders caused by toxic mutant genes.Nationally, Dr. Paulson has directed popular courses at the American Academy of Neurology meetings, serves on the scientific advisory boards of numerous disease-related national organizations, and is past Chair of the Board of Scientific Counselors at the National Institute for Neurological Disorders and Stroke at the National Institutes of Health.Among his awards, Dr. Paulson is an Ellison Medical Foundation New Scholar in Aging, a semifinalist for the W.M. Keck Foundation Young Scholars in Medical Research, and a recipient of the Paul Beeson Physician Faculty Scholar in Aging Award from the American Federation for Aging Research. Dr. Paulson is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia. He is also highly rated in 41 other conditions, according to our data. His clinical expertise encompasses Olivopontocerebellar Atrophy, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia, and Drug Induced Dyskinesia. Dr. Paulson is board certified in Neurology.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Spinocerebellar Ataxia
Elite in Spinocerebellar Ataxia
Referral may be required

Office

300 Medical Plz, 
Los Angeles, CA 
Languages Spoken:
English
Offers Telehealth

Susan Perlman is a Neurologist practicing medicine in Los Angeles, California. Dr. Perlman is rated as an Elite provider by MediFind in the treatment of Spinocerebellar Ataxia. She is also highly rated in 53 other conditions, according to our data. Her clinical expertise encompasses Spinocerebellar Ataxia, Friedreich Ataxia, Drug Induced Dyskinesia, and Olivopontocerebellar Atrophy.

What are the latest Spinocerebellar Ataxia Clinical Trials?
A Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omaveloxolone (BIIB141) in Participants With Friedreich's Ataxia Aged 2 to < 16 Years

Summary: In this study, researchers will learn more about omaveloxolone, also known as BIIB141 or SKYCLARYS®. Omaveloxolone is already approved for people with Friedreich's Ataxia (FA) who are 16 years of age or older. However, it is not yet available for younger teens and children. The main goal of this study is to learn how omaveloxolone affects symptoms of FA and its safety in younger participants betwe...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Characteristics And Clinical Course Of Disease In Participants With Cardiomyopathy Associated With Friedreich Ataxia (CLARITY-FA)

Summary: Characteristics and clinical course of disease In participants with cardiomyopathy associated with Friedreich Ataxia (CLARITY-FA)